Amneal Pharmaceuticals (AMRX) earnings

Earnings (net income) · fiscal 2025
$72.06M

Amneal Pharmaceuticals (AMRX) reported net income of $72.06M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$116.89M. Figures as of 18 Nov 2026, 04:34 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Earnings (net income), fiscal 2025
$72.06M
Growth, 5 years
+1.2% a year
Highest on record
$72.06Mfiscal 2025
Lowest on record
-$603.57Mfiscal 2019
Fiscal years on record
102016–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Amneal Pharmaceuticals earnings, in more detail

Over the five fiscal years to 2025 net income grew at a compound 1.2% a year. Across the 10 fiscal years on record (2016–2025), the highest was $72.06M in fiscal 2025 and the lowest -$603.57M in fiscal 2019.

History · 10 fiscal years

Earnings (net income) by fiscal year

Amneal Pharmaceuticals earnings, year by year

Amneal Pharmaceuticals (AMRX) earnings by fiscal year
Fiscal yearEarnings (net income)ChangeYear ended
2025$72.06M—
2024-$116.89M—
2023-$83.99M—
2022-$129.99M 1,087.5% down
2021$13.16M 80.6% down
2020$67.79M—
2019-$603.57M—
2018-$19.74M—
2017$0.00—
2016$0.00—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

How to read it

Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.

Earnings (net income) at health care companies of similar size

Earnings (net income) of Amneal Pharmaceuticals and comparable companies
CompanyEarnings (net income)Fiscal year
Cytokinetics CYTK-$784.96M2025
ABIVAX ABVX-€336.10M2025
Bausch + Lomb BLCO-$360.00M2025
Amneal Pharmaceuticals AMRX$72.06M2025
Caris Life Sciences CAI-$68.09M2025
Immunovant IMVT-$505.61M2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on AMRX

Amneal Pharmaceuticals, figure by figure

Amneal Pharmaceuticals (AMRX) overview: price, valuation and scorecardAll health care companies by market value

Amneal Pharmaceuticals earnings: questions and answers

What is Amneal Pharmaceuticals's net income?

Amneal Pharmaceuticals (AMRX) reported net income of $72.06M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$116.89M.

What is the growth rate of Amneal Pharmaceuticals's net income?

Over the five fiscal years to 2025 net income grew at a compound 1.2% a year.

What are the highest and lowest net income figures on record for Amneal Pharmaceuticals?

Across the 10 fiscal years on record (2016–2025), the highest was $72.06M in fiscal 2025 and the lowest -$603.57M in fiscal 2019.

How is Amneal Pharmaceuticals's net income calculated?

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Amneal Pharmaceuticals (AMRX) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/AMRX/earnings

Underlying data: the company's filings with the SEC and Yahoo Finance.